LeonaBio, Inc. Costs and Expenses
LeonaBio, Inc. (LONA) reported Costs and Expenses of $19.45 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2026-08-14
- LeonaBio, Inc. costs and expenses for the quarter ending 2026-06-30 was $19.45M, a 166.81% increase year-over-year.
- LeonaBio, Inc. costs and expenses for the quarter ending 2026-03-31 was $17.21M, a 80.52% increase year-over-year.
- LeonaBio, Inc. costs and expenses for the quarter ending 2025-12-31 was $78.56M, a 404.72% increase year-over-year.
- LeonaBio, Inc. costs and expenses for the quarter ending 2025-09-30 was $6.87M, a 76.79% decline year-over-year.
- LeonaBio, Inc. costs and expenses for fiscal 2025 was $102.27M, a 1.35% increase from fiscal 2024.
- LeonaBio, Inc. costs and expenses for fiscal 2024 was $100.90M, a 19.58% decline from fiscal 2023.
- LeonaBio, Inc. costs and expenses for fiscal 2023 was $125.47M, a 20.62% increase from fiscal 2022.
- LeonaBio, Inc. costs and expenses for fiscal 2022 was $104.02M, a 62.47% increase from fiscal 2021.
| Period end | Costs and Expenses 3 month | Costs and Expenses 6 month | Costs and Expenses 9 month | Costs and Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $19.45M 10-Q · filed 2026-08-14 | $36.67M 10-Q · filed 2026-08-14 | $115.23M derived: sum of 3 quarters · filed 2026-08-14 | $122.11M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $17.21M 10-Q · filed 2026-05-07 | $95.78M derived: sum of 2 quarters · filed 2026-05-07 | $102.65M derived: sum of 3 quarters · filed 2026-05-07 | $109.94M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $78.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $85.44M derived: sum of 2 quarters · filed 2026-03-31 | $92.73M derived: sum of 3 quarters · filed 2026-08-14 | $102.27M 10-K · filed 2026-03-31 |
| 2025-09-30 | $6.87M 10-Q · filed 2025-11-06 | $14.16M derived: sum of 2 quarters · filed 2026-08-14 | $23.70M 10-Q · filed 2025-11-06 | $39.27M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $7.29M 10-Q · filed 2026-08-14 | $16.83M 10-Q · filed 2026-08-14 | $32.39M derived: sum of 3 quarters · filed 2026-08-14 | $62.01M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $9.54M 10-Q · filed 2026-05-07 | $25.10M derived: sum of 2 quarters · filed 2026-05-07 | $54.72M derived: sum of 3 quarters · filed 2026-05-07 | $82.75M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $15.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $45.19M derived: sum of 2 quarters · filed 2026-03-31 | $73.22M derived: sum of 3 quarters · filed 2026-03-31 | $100.90M 10-K · filed 2026-03-31 |
| 2024-09-30 | $29.62M 10-Q · filed 2025-11-06 | $57.65M derived: sum of 2 quarters · filed 2025-11-06 | $85.34M 10-Q · filed 2025-11-06 | $114.35M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $28.03M 10-Q · filed 2025-08-07 | $55.72M 10-Q · filed 2025-08-07 | $84.73M derived: sum of 3 quarters · filed 2025-08-07 | $119.77M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $27.69M 10-Q · filed 2025-05-09 | $56.70M derived: sum of 2 quarters · filed 2025-05-09 | $91.74M derived: sum of 3 quarters · filed 2025-05-09 | $123.38M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $29.01M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $64.06M derived: sum of 2 quarters · filed 2025-02-27 | $95.70M derived: sum of 3 quarters · filed 2025-02-27 | $125.47M 10-K · filed 2025-02-27 |
| 2023-09-30 | $35.04M 10-Q · filed 2024-11-07 | $66.68M derived: sum of 2 quarters · filed 2024-11-07 | $96.45M 10-Q · filed 2024-11-07 | $129.38M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $31.64M 10-Q · filed 2024-08-01 | $61.41M 10-Q · filed 2024-08-01 | $94.34M derived: sum of 3 quarters · filed 2024-08-01 | $118.47M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $29.77M 10-Q · filed 2024-05-15 | $62.70M derived: sum of 2 quarters · filed 2024-05-15 | $86.83M derived: sum of 3 quarters · filed 2024-05-15 | $110.40M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $32.93M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $57.06M derived: sum of 2 quarters · filed 2024-02-22 | $80.63M derived: sum of 3 quarters · filed 2024-02-22 | $104.02M 10-K · filed 2024-02-22 |
| 2022-09-30 | $24.13M 10-Q · filed 2023-11-09 | $47.70M derived: sum of 2 quarters · filed 2023-11-09 | $71.09M 10-Q · filed 2023-11-09 | $89.87M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $23.57M 10-Q · filed 2023-08-10 | $46.96M 10-Q · filed 2023-08-10 | $65.73M derived: sum of 3 quarters · filed 2023-08-10 | $83.56M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $23.39M 10-Q · filed 2023-05-11 | $42.16M derived: sum of 2 quarters · filed 2023-05-11 | $59.99M derived: sum of 3 quarters · filed 2023-05-11 | $76.63M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $18.78M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $36.60M derived: sum of 2 quarters · filed 2023-03-23 | $53.24M derived: sum of 3 quarters · filed 2023-03-23 | $64.02M 10-K · filed 2023-03-23 |
| 2021-09-30 | $17.83M 10-Q · filed 2022-11-10 | $34.46M derived: sum of 2 quarters · filed 2022-11-10 | $45.24M 10-Q · filed 2022-11-10 | $54.32M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $16.64M 10-Q · filed 2022-08-15 | $27.42M 10-Q · filed 2022-08-15 | $36.50M derived: sum of 3 quarters · filed 2022-08-15 | $43.89M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $10.78M 10-Q · filed 2022-05-12 | $19.86M derived: sum of 2 quarters · filed 2022-05-12 | $27.26M derived: sum of 3 quarters · filed 2022-05-12 | $29.51M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $9.08M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $16.48M derived: sum of 2 quarters · filed 2022-03-28 | $18.73M derived: sum of 3 quarters · filed 2022-03-28 | $20.00M 10-K · filed 2022-03-28 |
| 2020-09-30 | $7.40M 10-Q · filed 2021-11-10 | $9.65M derived: sum of 2 quarters · filed 2021-11-10 | $10.92M 10-Q · filed 2021-11-10 | $12.03M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $2.25M 10-Q · filed 2021-08-16 | $3.52M 10-Q · filed 2021-08-16 | $4.64M derived: sum of 3 quarters · filed 2021-08-16 | $6.17M derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | $1.27M 10-Q · filed 2021-05-13 | $2.38M derived: sum of 2 quarters · filed 2021-05-13 | $3.92M derived: sum of 3 quarters · filed 2021-05-13 | |
| 2019-12-31 | $1.12M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $2.65M derived: sum of 2 quarters · filed 2021-03-25 | $5.45M 10-K · filed 2021-03-25 | |
| 2019-09-30 | $1.53M 10-Q · filed 2020-11-12 | $4.33M 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |